Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338291 | 1.00 | FFAR1 (0.48) | FFAR1FFAR4PLA2G10PLA2G2ASLCO1B1 | |
| Propionic Acid SCHEMBL15134966 | 0.96 | FFAR1 (0.45) | FFAR1FFAR4PLA2G10PLA2G2ASLCO1B1 | |
| Propionic Acid SCHEMBL15134963 | 0.96 | FFAR1 (0.45) | FFAR1FFAR4PLA2G10PLA2G2ASLCO1B1 | |
| SCHEMBL12129716 | 0.83 | CYP4F2 (0.51) | NPSR1 | |
| SCHEMBL15134965 | 0.82 | L3MBTL1 (0.39) | FFAR1FFAR4 | |
| Propionic Acid SCHEMBL15134954 | 0.82 | L3MBTL1 (0.37) | FFAR1FFAR4 | |
| Propionic Acid SCHEMBL15134955 | 0.82 | L3MBTL1 (0.37) | FFAR1FFAR4 | |
| SCHEMBL3456074 | 0.82 | GAA (0.55) | FFAR1FFAR4NPSR1 | |
| SCHEMBL3456072 | 0.82 | GAA (0.55) | FFAR1FFAR4NPSR1 | |
| SCHEMBL10180092 | 0.81 | L3MBTL1 (0.38) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2387571-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | Almirall S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-8041930-B2 | Data processing apparatus and method for controlling thread access of register sets when selectively operating in secure and non-secure domains | ARM LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-2250165-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | Merck Serono S.A. (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081692-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | ALMIRALL, S.A. (ES) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | FFAR1 35/4885FFAR4 75/4885PLA2G10 889/4885 |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | FFAR1 2458/4885FFAR4 2908/4885PLA2G10 4827/4885 |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | S1PR1, S1PR3, S1PR2 | FFAR1 27/4885FFAR4 80/4885PLA2G10 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.